Cargando…
c.9253-6T > c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by dysplasias, ineffective hematopoiesis and risk of acute myeloid leukemia transformation. Approximately 90% of MDS patients present mutations in genes involved in various cell signaling pathways....
Autores principales: | Oliveira, Roberta Taiane G. de, França, Ivo Gabriel. F., Junior, Howard L.R., Riello, Giovanna B.C., Borges, Daniela de Paula, Cavalcante, Gabrielle Melo, Magalhães, Silvia M.M., Pinheiro, Ronald F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446231/ https://www.ncbi.nlm.nih.gov/pubmed/32682781 http://dx.doi.org/10.1016/j.htct.2020.05.006 |
Ejemplares similares
-
Role of conventional cytogenetics in sequential karyotype analysis of myelodysplastic syndrome: a patient with der(1;7)(q10;p10)
por: França, Ivo Gabriel da Frota, et al.
Publicado: (2019) -
Myelodysplastic syndrome patients present more severe respiratory muscle impairment and reduced forced vital capacity: Is disordered inflammatory signaling the culprit?
por: Okubo, Bruno Memória, et al.
Publicado: (2017) -
Instructions No.1 for the E.i.C. (Rev.)
Publicado: (1960) -
In Memoriam—Rev. C. P. Jennings, M. D.
Publicado: (1895) -
USP15-USP7 Axis and UBE2T Differential Expression May Predict Pathogenesis and Poor Prognosis in De Novo Myelodysplastic Neoplasm
por: de Carvalho, Luiz Gustavo Almeida, et al.
Publicado: (2023)